
 OMB APPROVAL

 OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden
 hours per response.....0.5

U.S. SECURITIES AND EXCHANGE COMMISSION
 Washington, DC 20549

FORM 3

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or
 Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person

Weiser	Michael	
(Last)	(First)	(Middle)

130 East 75/th/ Street

(Street)

New York	NY	10021
(City)	(State)	(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)

February 21, 2003

3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)

4. Issuer Name and Ticker or Trading Symbol

Manhattan Pharmaceuticals, Inc. (f/k/a Atlantic Technology Ventures, Inc.)
 (ATLC.OB)

5. Relationship of Reporting Person to Issuer
 (Check all applicable)

<input checked="" type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
<input type="checkbox"/> Officer (give title below)	<input type="checkbox"/> Other (specify below)

6. If Amendment, Date of Original (Month/Day/Year)

February 21, 2003

7. Individual or Joint/Group Filing (Check applicable line)

Form Filed by One Reporting Person
 Form Filed by More than One Reporting Person

=====

TABLE I -- NON-DERIVATIVE SECURITIES BENEFICIALLY OWNED

=====

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	6,837,806	D	

=====

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

